- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301 Low Dose, CVT-301 High Dose, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 1,667
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Standard of Care Chemotherapy
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Anal Dysplasia, Carcinoma in Situ
- Interventions
- Gliolan, Vitamin D3 cholecalciferol), Photodynamic Therpay
- Drug · Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Otitis Media
- Interventions
- amoxicillin/clavulanate postassium (Augmentin ES-600), azithromycin SR
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 48 Months
- Enrollment
- 902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 23
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Bellflower, California + 18 more
- Conditions
- Bronchiectasis
- Interventions
- BI 1291583, Placebo matching BI 1291583
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more
- Conditions
- Prostate Cancer
- Interventions
- Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
- Interventions
- Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
- Drug · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
- Conditions
- Palmar Hyperhidrosis
- Interventions
- Dexmecamylamine HCl, Placebo
- Drug · Other
- Lead sponsor
- Atacama Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- San Diego, California • St Louis, Missouri • Norfolk, Virginia
- Conditions
- Leukemia, Lymphoma
- Interventions
- Capivasertib, Venetoclax, Rituximab, Blinatumomab, Nelarabine, mini-hyperCVD
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Scoliosis
- Interventions
- Methadone based ERAS, Non-methadone based group
- Drug
- Lead sponsor
- Senthil Sadhasivam
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more
- Conditions
- HIV Infection, HIV
- Interventions
- Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Asthma
- Interventions
- Dupilumab SAR231893 (REGN668)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
- Conditions
- Cystic Fibrosis
- Interventions
- IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Laromustine (VNP40101M) and Ara-C
- Drug
- Lead sponsor
- Viron Therapeutics Inc
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Glofitamab, Obinutuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
- Conditions
- Breast Cancer
- Interventions
- contrast enhanced mammography, Iodinated Contrast Media (ICM)
- Device · Drug
- Lead sponsor
- Margarita Louise Zuley
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 2,089 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Drug: 99mTc-MIP-1404
- Drug
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 10
- States / cities
- Duarte, California • Rochester, Minnesota • New York, New York + 7 more
- Conditions
- Solid Tumor
- Interventions
- haNK™ for Infusion
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Glioblastoma Multiforme
- Interventions
- VBI-1901, Carmustine, Lomustine
- Biological · Drug
- Lead sponsor
- VBI Vaccines Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 8 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
- Conditions
- Familial Hypercholesterolemia - Heterozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
- Conditions
- Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
- Interventions
- Follow-up booster Alert, Pre-commitment, Enhanced Alert
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia
- Interventions
- cytarabine, daunorubicin hydrochloride, etoposide, tipifarnib, chemotherapy, enzyme inhibitor therapy, high-dose chemotherapy
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Columbus, Ohio